Legislation Search

H.R. 1266: Combating Illicit Xylazine Act

This bill, titled the Combating Illicit Xylazine Act, aims to regulate the use of xylazine, a substance that has been increasingly associated with illicit drug use. Here are the main points of the bill:

1. Definition and Classification

The bill defines xylazine and includes it as a substance under the Controlled Substances Act. It specifies that xylazine will be classified as a Schedule III controlled substance. This means that while it has legitimate medical uses, it also has a potential for abuse and addiction.

2. Controlled Substances Act Amendments

The bill proposes several amendments to the Controlled Substances Act:

Xylazine will be included in the definition of controlled substances, indicating its legal and regulated status.
Manufacturers producing xylazine will not be required to implement the security measures immediately, easing their transition to compliance.
Labeling and packaging requirements related to xylazine will not be enforced until one year after the bill's enactment.
Practitioners handling xylazine will have a grace period of 60 days from enactment to register and comply with recordkeeping requirements.

3. Use by Veterinarians

The bill clarifies that xylazine can still be prescribed and dispensed by licensed veterinarians, allowing its use for pets and other animals. It emphasizes that individuals or entities using xylazine for animals will not need to register as ultimate users, provided they meet certain conditions.

4. Tracking and Reporting

The bill mandates that the Drug Enforcement Administration (DEA) enhance its tracking systems to monitor the distribution and use of xylazine. This includes analyzing where the drug is being diverted and its sources of origin.

5. Sentencing Guidelines

The bill directs the United States Sentencing Commission to review and potentially amend sentencing guidelines for offenses related to xylazine, ensuring that penalties align with its new classification as a controlled substance.

6. Reports to Congress

The Attorney General is required to submit two reports to Congress within specified timeframes:

Within 18 months of enactment, a report detailing the prevalence and impact of illicit xylazine use.
Within four years of enactment, an updated report on the trafficking and misuse of xylazine.

7. Implications for Manufacturers and Practitioners

The bill recognizes that entities currently manufacturing xylazine will not face immediate additional costs related to security measures for manufacturing processes. It also allows practitioners to continue their activities while their registration applications are pending, promoting a smoother transition into compliance with the new regulations.

8. Cooperation between Agencies

Lastly, the bill emphasizes collaboration between the FDA and DEA to efficiently manage the transition of xylazine into the Schedule III classification, along with any related manufacturer submissions that might be necessary.

Relevant Companies

None found

This is an AI-generated summary of the bill text. There may be mistakes.

Actions

5 actions

Date	Action
Jun. 25, 2026	Forwarded by Subcommittee to Full Committee by Voice Vote.
Jun. 25, 2026	Subcommittee Consideration and Mark-up Session Held
Feb. 12, 2025	Introduced in House
Feb. 12, 2025	Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb. 12, 2025	Referred to the Subcommittee on Health.

Corporate Lobbying

0 companies lobbying

None found.

* Note that there can be significant delays in lobbying disclosures, and our data may be incomplete.

Potentially Relevant Congressional Stock Trades

No relevant congressional stock trades found.